Biology:NCI-60
The NCI-60 cancer cell line panel is a group of 60 human cancer cell lines used by the National Cancer Institute (NCI) for the screening of compounds to detect potential anticancer activity.[1]
Purpose
The screening procedure is called the NCI-60 Human Tumor Cell Lines Screen, and it is one of the Discovery & Development Services of NCI's Developmental Therapeutics Program (DTP).[2][3][4] The screening rates for each cell line the cytostatic and cytotoxic impact of tested substances.[2]
Due to the diversity of the cell lines, it is possible to compare tested compounds by their effect patterns, high correlation potentially corresponding to similar effect mechanisms.[2] An automated comparison against a database of more than 88,000 pure compounds and more than 34,000 crude extracts ((As of January 2017)) is provided by the COMPARE tool, which shows a list of substances ranked by the Pearson correlation coefficients for a given test substance.[5]
The same panel is used in the Molecular Target Program for the characterization of molecular targets. Measurements include protein levels, RNA measurements, mutation status and enzyme activity levels.[6]
Cell Lines
The panel holds cell lines representing leukemia, melanoma, non-small-cell lung carcinoma, and cancers of the brain, ovary, breast, colon, kidney, and prostate.[1][2]
13 additional cell lines are evaluated for use in the screening program, among them two lines deriving from so far not represented small-cell lung carcinoma.[1]
All cell lines but one ((As of January 2017)) are available to other laboratories, including the additional cell lines.[1]
Misidentification and Misclassification
Starting around the turn of the millennium, several cell lines were found to be misidentified or misclassified at the time of investigation or earlier:[7][8][9]
MDA-MB-435, originally classified as breast cancer cell line, was identified as being a melanoma cell line.[7] When investigated further, current MDA-MB-435 appeared to be derived from the same individual as cell line M14.[7] An examination of clones made clear that the mixup with M14 happened very early in the history of MDA-MB-435, before establishment in the Developmental Therapeutics Program.[7]
NCI/ADR-RES, originally classified as breast cancer cell line, was identified as being an ovarian tumor cell line.[8] NCI/ADR-RES appears to have been derived at some point in time from cell line OVCAR-8.[8] Originally the cell line was named MCF-7/ADR-RES; it was renamed together with the change in classification.[8]
Two brain cancer cell lines, SNB-19 and U251, were discovered to come from the same person.[9] This makes a mixup likely.
A 61st cell line, MDA-N, has been confirmed to being derived from the misclassified MDA-MB-435 cell line.[7] So it is also misclassified, really being a melanoma cell line, but (As of January 2018) the official website still lists it as breast cancer cell line.[1] This cell line is not available (As of January 2018).[1]
The International Cell Line Authentication Committee maintains a list of contaminated cell lines.[10] It includes the cell lines reported above, although usually with reporting dates and articles considerably later than the first dates and articles rising specific concern regarding the respective cell line.[10][7][8][9]
Continued Use of Wrong Classification
(As of 2014) Hundreds of research studies still use MDA-MB-435 as model of breast cancer, even after it was officially declared to be a melanoma cell line in 2007, and even in highest-rated international peer-reviewed journals.[11] Similar is true for other misidentified cell lines.[11]
List of NCI-60 Cell Lines
| Cell line | Tumor classification | (Potentially) misidentified | Original classification | Unavailable | Doubling Time (Hours) | Inoculation Density | Cellosaurus identifier and link | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CCRF-CEM | Leukemia | 26.7 | 40000 | CCRF-CEM (RRID:CVCL_0207) | ||||||||||||
| HL-60(TB) | Leukemia | 28.6 | 40000 | HL-60(TB) (RRID:CVCL_A794) | ||||||||||||
| K-562 | Leukemia | 19.6 | 5000 | K-562 (RRID:CVCL_0004) | ||||||||||||
| MOLT-4 | Leukemia | 27.9 | 30000 | MOLT-4 (RRID:CVCL_0013) | ||||||||||||
| RPMI-8226 | Leukemia | 33.5 | 20000 | RPMI-8226 (RRID:CVCL_0014) | ||||||||||||
| SR-786 | Leukemia | 28.7 | 20000 | SR (RRID:CVCL_1711) | ||||||||||||
| A549 | Non-Small Cell Lung | 22.9 | 7500 | A-549 (RRID:CVCL_0023) | ||||||||||||
| EKVX | Non-Small Cell Lung | 43.6 | 20000 | EKVX (RRID:CVCL_1195) | ||||||||||||
| HOP-62 | Non-Small Cell Lung | 39 | 10000 | HOP-62 (RRID:CVCL_1285) | ||||||||||||
| HOP-92 | Non-Small Cell Lung | 79.5 | 20000 | HOP-92 (RRID:CVCL_1286) | ||||||||||||
| NCI-H226 | Non-Small Cell Lung | 61 | 20000 | NCI-H226 (RRID:CVCL_1544) | ||||||||||||
| NCI-H23 | Non-Small Cell Lung | 33.4 | 20000 | NCI-H23 (RRID:CVCL_1547) | ||||||||||||
| NCI-H322M | Non-Small Cell Lung | 35.3 | 20000 | NCI-H322M (RRID:CVCL_1557) | ||||||||||||
| NCI-H460 | Non-Small Cell Lung | 17.8 | 7500 | NCI-H460 (RRID:CVCL_0459) | ||||||||||||
| NCI-H522 | Non-Small Cell Lung | 38.2 | 20000 | NCI-H522 (RRID:CVCL_1567) | ||||||||||||
| COLO 205 | Colon | 23.8 | 15000 | COLO 205 (RRID:CVCL_0218) | ||||||||||||
| HCC-2998 | Colon | 31.5 | 15000 | HCC2998 (RRID:CVCL_1266) | ||||||||||||
| HCT116 | Colon | 17.4 | 5000 | HCT 116 (RRID:CVCL_0291) | ||||||||||||
| HCT-15 | Colon | 20.6 | 10000 | HCT 15 (RRID:CVCL_0292) | ||||||||||||
| HT-29 | Colon | 19.5 | 5000 | HT-29 (RRID:CVCL_0320) | ||||||||||||
| KM12 | Colon | 23.7 | 15000 | KM12 (RRID:CVCL_1331) | ||||||||||||
| SW-620 | Colon | 20.4 | 10000 | SW620 (RRID:CVCL_0547) | ||||||||||||
| SF-268 | CNS | 33.1 | 15000 | SF268 (RRID:CVCL_1689) | ||||||||||||
| SF-295 | CNS | 29.5 | 10000 | SF295 (RRID:CVCL_1690) | ||||||||||||
| SF-539 | CNS | 35.4 | 15000 | SF539 (RRID:CVCL_1691) | ||||||||||||
| SNB-19 | CNS | yes | CNS | 34.6 | 15000 | SNB-19 (RRID:CVCL_0535) | ||||||||||
| SNB-75 | CNS | 62.8 | 20000 | SNB-75 (RRID:CVCL_1706) | ||||||||||||
| U251 | CNS | yes | CNS | 23.8 | 7500 | U-251MG (RRID:CVCL_0021) | ||||||||||
| LOX IMVI | Melanoma | 20.5 | 7500 | LOX-IMVI (RRID:CVCL_1381) | ||||||||||||
| MALME-3M | Melanoma | 46.2 | 20000 | Malme-3M (RRID:CVCL_1438) | ||||||||||||
| M14 | Melanoma | 26.3 | 15000 | M14 (RRID:CVCL_1395) | ||||||||||||
| MDA-MB-435 | Melanoma | yes | Breast | 25.8 | 15000 | MDA-MB-435 (RRID:CVCL_0417) | ||||||||||
| SK-MEL-2 | Melanoma | 45.5 | 20000 | SK-MEL-2 (RRID:CVCL_0069) | ||||||||||||
| SK-MEL-28 | Melanoma | 35.1 | 10000 | SK-MEL-28 (RRID:CVCL_0526) | ||||||||||||
| SK-MEL-5 | Melanoma | 25.2 | 10000 | SK-MEL-5 (RRID:CVCL_0527) | ||||||||||||
| UACC-257 | Melanoma | 38.5 | 20000 | UACC-257 (RRID:CVCL_1779) | ||||||||||||
| UACC-62 | Melanoma | 31.3 | 10000 | UACC-62 (RRID:CVCL_1780) | ||||||||||||
| IGROV-1 | Ovarian | 31 | 10000 | IGROV-1 (RRID:CVCL_1304) | ||||||||||||
| OVCAR-3 | Ovarian | 34.7 | 10000 | OVCAR-3 (RRID:CVCL_0465) | ||||||||||||
| OVCAR-4 | Ovarian | 41.4 | 15000 | OVCAR-4 (RRID:CVCL_1627) | ||||||||||||
| OVCAR-5 | Ovarian | 48.8 | 20000 | OVCAR-5 (RRID:CVCL_1628) | ||||||||||||
| OVCAR-8 | Ovarian | 26.1 | 10000 | OVCAR-8 (RRID:CVCL_1629) | ||||||||||||
| NCI/ADR-RES (originally MCF-7/ADR-RES) | Ovarian | yes | Breast | 34 | 15000 | NCI-ADR-RES (RRID:CVCL_1452) | ||||||||||
| SK-OV-3 | Ovarian | 48.7 | 20000 | SK-OV-3 (RRID:CVCL_0532) | ||||||||||||
| 786-O | Renal | 22.4 | 10000 | 786-O (RRID:CVCL_1051) | ||||||||||||
| A498 | Renal | 66.8 | 25000 | A-498 (RRID:CVCL_1056) | ||||||||||||
| ACHN | Renal | 27.5 | 10000 | ACHN (RRID:CVCL_1067) | ||||||||||||
| CAKI-1 | Renal | 39 | 10000 | Caki-1 (RRID:CVCL_0234) | ||||||||||||
| RXF 393 | Renal | 62.9 | 15000 | RXF 393L (RRID:CVCL_1673) | ||||||||||||
| SN12C | Renal | 29.5 | 15000 | SN12C (RRID:CVCL_1705) | ||||||||||||
| TK-10 | Renal | 51.3 | 15000 | TK-10 (RRID:CVCL_1773) | ||||||||||||
| UO-31 | Renal | 41.7 | 15000 | UO-31 (RRID:CVCL_1911) | ||||||||||||
| PC-3 | Prostate | 27.1 | 7500 | PC-3 (RRID:CVCL_0035) | ||||||||||||
| DU-145 | Prostate | 32.3 | 10000 | DU145 (RRID:CVCL_0105) | ||||||||||||
| MCF7 | Breast | 25.4 | 10000 | MCF-7 (RRID:CVCL_0031) | ||||||||||||
| MDA-MB-231 | Breast | 41.9 | 20000 | MDA-MB-231 (RRID:CVCL_0062) | ||||||||||||
| MDA-MB-468 | Breast | 62 | 2000 | MDA-MB-468 (RRID:CVCL_0419) | HS 578T | Breast | 53.8 | 20000 | Hs 578T (RRID:CVCL_0332) | |||||||
| MDA-N | Melanoma | yes | Breast | unavailable | 22.5 | 15000 | MDA-N (RRID:CVCL_1910) | |||||||||
| BT-549 | Breast | 53.9 | 20000 | BT-549 (RRID:CVCL_1092) | ||||||||||||
| T-47D | Breast | 45.5 | 20000 | T-47D (RRID:CVCL_0553) |
List of Additional Cell Lines
| Cell line | Tumor classification | Species | Inoculation Density | Cellosaurus identifier and link |
|---|---|---|---|---|
| LXFL 529 | Non-Small Cell Lung | human | 10000 | LXFL 529L (RRID:CVCL_D085) |
| DMS 114 | Small Cell Lung | human | 20000 | DMS 114 (RRID:CVCL_1174) |
| SHP-77 | Small Cell Lung | human | 40000 | SHP-77 (RRID:CVCL_1693) |
| DLD-1 | Colon | human | 50000 | DLD-1 (RRID:CVCL_0248) |
| KM20L2 | Colon | human | 10000 | KM20L2 (RRID:CVCL_D889) |
| SNB-78 | CNS | human | 20000 | SNB-78 (RRID:CVCL_B321) |
| XF 498 | CNS | human | 20000 | XF 498 (RRID:CVCL_8928) |
| RPMI-7951 | Melanoma | human | 20000 | RPMI-7951 (RRID:CVCL_1666) |
| M19-MEL | Melanoma | human | 10000 | M19-MEL (RRID:CVCL_B415) |
| RXF-631 | Renal | human | 10000 | RXF 631L (RRID:CVCL_A780) |
| SN12K1 | Renal | human | 10000 | SN12K1 (RRID:CVCL_D106) |
| P388 | Leukemia | mouse | 50000 | P388 (RRID:CVCL_7222) |
| P388/ADR | Leukemia | mouse | 50000 | P388/ADR (RRID:CVCL_IZ75) |
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 "Cell Lines in the In Vitro Screen". National Cancer Institute. 8 May 2015. https://dtp.cancer.gov/discovery_development/nci-60/cell_list.htm.
- ↑ 2.0 2.1 2.2 2.3 "NCI-60 Human Tumor Cell Lines Screen". National Cancer Institute. 26 August 2015. https://dtp.cancer.gov/discovery_development/nci-60/default.htm.
- ↑ "Discovery & Development Services". National Cancer Institute. 26 August 2015. https://dtp.cancer.gov/discovery_development/default.htm.
- ↑ "Welcome to the Developmental Therapeutics Program". National Cancer Institute. https://dtp.cancer.gov/.
- ↑ "COMPARE Analysis". National Cancer Institute. 11 August 2015. https://dtp.cancer.gov/databases_tools/compare.htm.
- ↑ "Molecular Targets". National Cancer Institute. 12 May 2015. https://dtp.cancer.gov/databases_tools/molecular_target/default.htm.
- ↑ 7.0 7.1 7.2 7.3 7.4 7.5 "MDA-MB-435, and its derivation MDA-N, are Melanoma cell lines, not breast cancer cell lines.". National Cancer Institute. 8 May 2015. https://dtp.cancer.gov/discovery_development/nci-60/mda-mb-435.htm.
- ↑ 8.0 8.1 8.2 8.3 8.4 "Cell Line NCI/ADR-RES is an Ovarian tumor cell line, not a Breast line.". National Cancer Institute. 8 May 2015. https://dtp.cancer.gov/discovery_development/nci-60/nci-adrres.htm.
- ↑ 9.0 9.1 9.2 "CNS cell lines SNB-19 and U251 are derived from the same individual.". National Cancer Institute. 8 May 2015. https://dtp.cancer.gov/discovery_development/nci-60/u251_snb-19.htm.
- ↑ 10.0 10.1 Database of Cross-Contaminated or Misidentified Cell Lines, 8.0, International Cell Line Authentication Committee (ICLAC), 1 December 2016, http://iclac.org/wp-content/uploads/Cross-Contaminations-v8_0.pdf, retrieved 6 January 2018
- ↑ 11.0 11.1 Prasad, Vidudala VTS; Gopalan, Ramprasad OG (2 June 2015). "Continued use of MDA-MB-435, a melanoma cell line, as a model for human breast cancer, even in year, 2014". npj Breast Cancer 1: 15002–. doi:10.1038/npjbcancer.2015.2. PMID 28721362.
- ↑ 12.0 12.1 "Cellosaurus search result: 61 hits for "NCI60 cancer cell line panel"". Swiss Institute of Bioinformatics. https://www.cellosaurus.org/search?input=%22NCI60%20cancer%20cell%20line%20panel%22. The reference includes the list of linked pages in the search result.
- ↑ "Cellosaurus - a knowledge resource on cell lines". Swiss Institute of Bioinformatics. https://www.cellosaurus.org/. The reference includes the pages found by searching with the respective cell line names as given in the List of Additional Cell Lines.
 |  |
